AEON logo

AEON BiopharmaNYSEAM:AEON Stock Report

Market Cap US$8.8m
Share Price
US$0.81
My Fair Value
US$7.20
88.8% undervalued intrinsic discount
1Y-99.5%
7D-2.9%
Portfolio Value
View

AEON Biopharma (AEON) Stock Overview

A clinical stage biopharmaceutical company, focuses on developing botulinum toxins. More details

AEON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health0/6
Dividends0/6

AEON Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

AEON Biopharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AEON Biopharma
Historical stock prices
Current Share PriceUS$0.81
52 Week HighUS$215.31
52 Week LowUS$0.38
Beta0.70
1 Month Change8.87%
3 Month Change100.00%
1 Year Change-99.52%
3 Year Change-99.89%
5 Year Changen/a
Change since IPO-99.88%

Recent News & Updates

Recent updates

Shareholder Returns

AEONUS BiotechsUS Market
7D-2.9%-1.7%0.8%
1Y-99.5%-13.2%13.7%

Return vs Industry: AEON underperformed the US Biotechs industry which returned -11.9% over the past year.

Return vs Market: AEON underperformed the US Market which returned 14.8% over the past year.

Price Volatility

Is AEON's price volatile compared to industry and market?
AEON volatility
AEON Average Weekly Movement12.6%
Biotechs Industry Average Movement11.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: AEON's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AEON's weekly volatility has decreased from 27% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a5Rob Bancroftwww.aeonbiopharma.com

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Biopharma, Inc. Fundamentals Summary

How do AEON Biopharma's earnings and revenue compare to its market cap?
AEON fundamental statistics
Market capUS$8.84m
Earnings (TTM)US$169.12m
Revenue (TTM)n/a
0.1x
P/E Ratio
0.0x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AEON income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other Expenses-US$169.12m
EarningsUS$169.12m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)14.96
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-117.6%

How did AEON perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 12:25
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AEON Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation